LinkedIn facebook twitter youtube
News archive


More than 11,000 participants from around the world are expected at the 24th Congress of the European Hematology Association (EHA) at the RAI Amsterdam at Europaplein 24, 1078 GZ in Amsterdam, The Netherlands on June 13-16, 2019, where the latest data on haematology research and development will be presented.

This is the most important congress of haematology in Europe in which the latest developments and cutting-edge research in haematological diseases will be discussed. Find more information about the congress here.

If you are a myeloma patient advocate attending this congress, please find in this document all the relevant myeloma sessions that will be held at EHA 2019.

For the first time, the session covering advocacy topics (both Patient Advocacy Track and EHA Advocacy Sessions) have been merged into the Joint EHA advocacy and policy track. Find here all the sessions that will be held within this track. If you received a fellowship to attend EHA, attending these sessions is mandatory to be able to apply for a fellowship next year.

MPE Advocate Development Programme (ADP)

As with every year, the MPE Advocate Development Programme (ADP) will celebrates a face-to-face meeting during the EHA Annual Congress. The meeting will have 3 different parts: the EHA advocacy and policy track, two face-to-face meetings plus the poster workshop session.

Six advocates from five different countries (Sweden, Hungary, Germany, Spain and Italy) joined the ADP to learn about clinical research and development in myeloma and AL amyloidosis, mechanisms of accessing diagnostics and drugs, interaction with stakeholders such as  clinicians and industry and the basics of evidence-based advocacy. Find more information here.





Recent news

» Myeloma Patients Europe report finds huge inequalities in access to myeloma clinical trials in Central and Eastern Europe

» Horizon Europe research project looks to improve the affordability and sustainability of innovative health technologies

Leave a Reply

Your email address will not be published.

I accept the Privacy Policy